- Home
- IPM vs RVPH Comparison
IPM vs RVPH Comparison
Compare IPM & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- RVPH
- Stock Information
- Founded
- IPM 2005
- RVPH 2006
- Country
- IPM United States
- RVPH United States
- Employees
- IPM N/A
- RVPH N/A
- Industry
- IPM
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- IPM
- RVPH Health Care
- Exchange
- IPM NYSE
- RVPH Nasdaq
- Market Cap
- IPM 27.9M
- RVPH 32.8M
- IPO Year
- IPM N/A
- RVPH N/A
- Fundamental
- Price
- IPM $2.08
- RVPH $0.40
- Analyst Decision
- IPM Strong Buy
- RVPH Strong Buy
- Analyst Count
- IPM 1
- RVPH 5
- Target Price
- IPM $6.00
- RVPH $9.00
- AVG Volume (30 Days)
- IPM 40.3K
- RVPH 3.9M
- Earning Date
- IPM 08-13-2025
- RVPH 08-13-2025
- Dividend Yield
- IPM N/A
- RVPH N/A
- EPS Growth
- IPM N/A
- RVPH N/A
- EPS
- IPM N/A
- RVPH N/A
- Revenue
- IPM $6,344,746.00
- RVPH N/A
- Revenue This Year
- IPM $1,957.49
- RVPH N/A
- Revenue Next Year
- IPM $17.96
- RVPH N/A
- P/E Ratio
- IPM N/A
- RVPH N/A
- Revenue Growth
- IPM 14.16
- RVPH N/A
- 52 Week Low
- IPM $1.52
- RVPH $0.30
- 52 Week High
- IPM $5.50
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- RVPH 37.92
- Support Level
- IPM N/A
- RVPH $0.38
- Resistance Level
- IPM N/A
- RVPH $0.45
- Average True Range (ATR)
- IPM 0.00
- RVPH 0.04
- MACD
- IPM 0.00
- RVPH 0.01
- Stochastic Oscillator
- IPM 0.00
- RVPH 59.36
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powers multimedia social applications.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.